Physician profile
Brian Quarton
NPI 1417951401
$3,916.92
in general payments reported to CMS, 2019-2025
33 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $121 · 2021: $521 · 2022: $487 · 2023: $825 · 2024: $681 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $632.69 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $473.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $435.99 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $299.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $276.21 | 2019-2024 | |
| Amgen INC. | $253.43 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $179.09 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $154.29 | 2019-2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.24 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $127.85 | 2022-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $118.66 | 2019-2025 | Spravato |
| Braeburn INC. | $110.57 | 2024-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $98.49 | 2023-2025 | Rexulti, Abilify Maintena, Jynarque |
| Amarin Pharma, INC. | $76.70 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $52.19 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $51.19 | 2021 | |
| Viatris Specialty LLC | $49.78 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $47.27 | 2019 | |
| Seqirus USA INC | $41.58 | 2025 | Flucelvax, Fluad |
| Lundbeck LLC | $41.27 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.69 | 2023-2024 | Xifaxan |
| Medtronic, INC. | $28.44 | 2022-2023 | Minimed 780g |
| Gilead Sciences, INC. | $24.16 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.43 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.36 | 2022 | |
| Abbott Laboratories | $16.69 | 2024 | Freestyle Libre 3 |
| Philips North America LLC | $15.72 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.51 | 2024 | Voquezna |
| Indivior INC. | $15.42 | 2024 | Sublocade |
| Mylan Specialty L.P. | $13.67 | 2023 | Yupelri |
| Qiagen, LLC | $13.44 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Quarton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.